ZA966075B - Protein formulation. - Google Patents

Protein formulation.

Info

Publication number
ZA966075B
ZA966075B ZA9606075A ZA966075A ZA966075B ZA 966075 B ZA966075 B ZA 966075B ZA 9606075 A ZA9606075 A ZA 9606075A ZA 966075 A ZA966075 A ZA 966075A ZA 966075 B ZA966075 B ZA 966075B
Authority
ZA
South Africa
Prior art keywords
protein formulation
formulation
protein
Prior art date
Application number
ZA9606075A
Other languages
English (en)
Inventor
James Andya
Jeffrey L Cleland
Chung C Hsu
Xanthe M Lam
David E Overcashier
Steven J Shire
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA966075(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA966075B publication Critical patent/ZA966075B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9606075A 1995-07-27 1996-07-17 Protein formulation. ZA966075B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27

Publications (1)

Publication Number Publication Date
ZA966075B true ZA966075B (en) 1998-01-19

Family

ID=24021032

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9606075A ZA966075B (en) 1995-07-27 1996-07-17 Protein formulation.
ZA9606240A ZA966240B (en) 1995-07-27 1996-07-23 Methods for treatment of allergic asthma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA9606240A ZA966240B (en) 1995-07-27 1996-07-23 Methods for treatment of allergic asthma.

Country Status (16)

Country Link
EP (1) EP0841946B2 (xx)
JP (1) JP4153560B2 (xx)
CN (2) CN101172100A (xx)
AR (1) AR003468A1 (xx)
AT (1) ATE225185T1 (xx)
AU (1) AU715338B2 (xx)
CA (1) CA2226624C (xx)
DE (1) DE69624116T3 (xx)
DK (1) DK0841946T4 (xx)
ES (1) ES2186796T5 (xx)
IL (1) IL122733A (xx)
MX (1) MX9800760A (xx)
PT (1) PT841946E (xx)
RU (1) RU2229288C2 (xx)
WO (1) WO1997004807A1 (xx)
ZA (2) ZA966075B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2115139B8 (en) * 2007-01-29 2015-03-18 Teknologian tutkimuskeskus VTT Oy Method for producing novel ige based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
JP5649451B2 (ja) * 2007-12-21 2015-01-07 シーエヌジェイ ホールディングス，インコーポレイテッド トレハロースを含む安定化第ｉｘ因子製剤
EP2346900A1 (en) 2008-10-29 2011-07-27 Wyeth LLC Methods for purification of single domain antigen binding molecules
CN104740631B (zh) * 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
HUE039209T2 (hu) * 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
CN104023743B (zh) * 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
CA2925416A1 (en) 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
US20230250191A1 (en) 2020-07-10 2023-08-10 Shanghai Jemincare Pharmaceutical Co., Ltd. Anti-ige engineered antibody and application thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
ATE264388T1 (de) * 1992-09-24 2004-04-15 Tanox Biosystems Inc Umgestaltete monoklonale antikörper gegen ein immunglobulinisotyp
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
IL122733A (en) 2001-09-13
DK0841946T3 (da) 2003-02-10
DE69624116T3 (de) 2009-07-09
WO1997004807A1 (en) 1997-02-13
CN101172099B (zh) 2012-02-15
ES2186796T5 (es) 2009-04-01
CN101172099A (zh) 2008-05-07
ATE225185T1 (de) 2002-10-15
AU6638196A (en) 1997-02-26
DE69624116D1 (de) 2002-11-07
EP0841946B2 (en) 2008-10-15
DE69624116T2 (de) 2003-06-18
EP0841946B1 (en) 2002-10-02
AR003468A1 (es) 1998-08-05
CA2226624C (en) 2013-07-16
EP0841946A1 (en) 1998-05-20
CN101172100A (zh) 2008-05-07
RU2229288C2 (ru) 2004-05-27
ZA966240B (en) 1998-01-23
ES2186796T3 (es) 2003-05-16
PT841946E (pt) 2003-02-28
JP4153560B2 (ja) 2008-09-24
JPH11510172A (ja) 1999-09-07
IL122733A0 (en) 1998-08-16
CA2226624A1 (en) 1997-02-13
MX9800760A (es) 1998-04-30
DK0841946T4 (da) 2009-02-16
AU715338B2 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
ZA966075B (en) Protein formulation.
ZA966148B (en) Novel formulation.
HK1011856A1 (en) Cement formulation.
ZA967315B (en) Biphenylamides.
ZA962338B (en) Oral 2-methyl-thieno-benzodiazepine formulation.
ZA967745B (en) Pharmaceutical formulations.
ZA969722B (en) Pharmaceutical formulations.
ZA965190B (en) Pharmaceutical composition.
HK1016472A1 (en) Activated protein c formulations.
MX213417B (es) Fenilpiridazinonas.
CY2359B1 (en) Pharmaceutical formulation.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
EP0578819A4 (en) Icam-related protein.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA968081B (en) Pharmaceutical composition.
GB9510830D0 (en) Proteins
ZA966399B (en) Endothelin-receptor-antagonists.
AU7520396A (en) Abl-interactor protein
ZA968185B (en) Protein.
ZA966750B (en) Halogenobenzimidazoles.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA967314B (en) Carbamoylcarboxamides.
GB9622436D0 (en) Protein
ZA9610467B (en) OB protein derivatives.